Friberg LE - Search Results

1

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.

Thorsted A, Bouchene S, Tano E, Castegren M, Lipcsey M, Sjölin J, Karlsson MO, Friberg LE, Nielsen EI. Thorsted A, et al. Among authors: friberg le. PLoS One. 2019 Feb 21;14(2):e0211981. doi: 10.1371/journal.pone.0211981. eCollection 2019. PLoS One. 2019. PMID: 30789941 Free PMC article.

2

Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Friberg LE, Freijs A, Sandström M, Karlsson MO. Friberg LE, et al. J Pharmacol Exp Ther. 2000 Nov;295(2):734-40. J Pharmacol Exp Ther. 2000. PMID: 11046112

3

Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.

Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R. Jonsson E, et al. Among authors: friberg le. Cancer Chemother Pharmacol. 2000;46(6):493-500. doi: 10.1007/s002800000181. Cancer Chemother Pharmacol. 2000. PMID: 11138463

4

Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).

Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Friberg LE, et al. Eur J Clin Pharmacol. 2000 Nov;56(8):567-74. doi: 10.1007/s002280000181. Eur J Clin Pharmacol. 2000. PMID: 11151746

5

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Friberg LE, et al. J Clin Oncol. 2002 Dec 15;20(24):4713-21. doi: 10.1200/JCO.2002.02.140. J Clin Oncol. 2002. PMID: 12488418

6

Mechanistic models for myelosuppression.

Friberg LE, Karlsson MO. Friberg LE, et al. Invest New Drugs. 2003 May;21(2):183-94. doi: 10.1023/a:1023573429626. Invest New Drugs. 2003. PMID: 12889739 Review.

7

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandström M, Xie R. Karlsson MO, et al. Among authors: friberg le. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):206-11. doi: 10.1111/j.1742-7843.2005.pto960310.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733216 Free article. Review.

8

Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.

Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO. Friberg LE, et al. Eur J Pharm Sci. 2005 May;25(1):163-73. doi: 10.1016/j.ejps.2005.02.006. Eur J Pharm Sci. 2005. PMID: 15854812

9

A tool for neutrophil guided dose adaptation in chemotherapy.

Wallin JE, Friberg LE, Karlsson MO. Wallin JE, et al. Among authors: friberg le. Comput Methods Programs Biomed. 2009 Mar;93(3):283-91. doi: 10.1016/j.cmpb.2008.10.011. Epub 2008 Dec 11. Comput Methods Programs Biomed. 2009. PMID: 19084287

10

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

Friberg LE, Vermeulen AM, Petersson KJ, Karlsson MO. Friberg LE, et al. Clin Pharmacol Ther. 2009 Apr;85(4):409-17. doi: 10.1038/clpt.2008.234. Epub 2008 Dec 24. Clin Pharmacol Ther. 2009. PMID: 19109590

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

186 results

Search Page